EP 0984956 A1 20000315 - INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS
Title (en)
INDOLINE DERIVATIVES AS 5HT2C RECEPTOR ANTAGONISTS
Title (de)
INDOLINDERIVATE ALS 5HT2C REZEPTOR ANTAGONISTEN
Title (fr)
DERIVES D'INDOLINE COMME ANTAGONISTES DU RECEPTEUR 5HT2C
Publication
Application
Priority
- EP 9802992 W 19980513
- GB 9710523 A 19970523
Abstract (en)
[origin: WO9852943A1] A compound of formula (I) or a salt thereof, wherein: R<1> is hydrogen or C1-6alkyl; R<2>, R<3> and R<4> groups are independently hydrogen, halogen or C1-6alkyl optionally substituted by one or more fluorine atoms. R<5> and R<6> groups are independently hydrogen or C1-6alkyl; X and Y are independently CH or nitrogen, provided that X is nitrogen when Y is nitrogen and both R<5> and R<6> are hydrogen. The compounds exhibit enhanced 5HT2C receptor antagonist activity profile. 5HT2C receptor antagonists are believed to be of potential use in the treatment of CNS disorders such as anxiety, depression, epilepsy, obsessive compulsive disorders, migraine, Alzheimer's disease, sleep disorders, feeding disorders such as anorexia and bulimia, panic attacks, withdrawal from drug abuse such as cocaine, ethanol, nicotine and benzodiazepines, schizophrenia, and also disorders associated with spinal trauma and/or head injury such as hydrocephalus. Compounds of the invention are also expected to be of use in the treatment of glaucoma, certain GI (gastrointestinal) disorders such as IBS (Irritable Bowel Syndrome) as well as microvascular diseases such as macular oedema and retinopathy.
IPC 1-7
IPC 8 full level
A61K 31/4439 (2006.01); A61K 31/497 (2006.01); A61P 25/00 (2006.01); A61P 25/06 (2006.01); A61P 25/08 (2006.01); A61P 25/18 (2006.01); A61P 25/20 (2006.01); A61P 25/22 (2006.01); A61P 25/24 (2006.01); A61P 25/28 (2006.01); A61P 25/30 (2006.01); A61P 27/02 (2006.01); A61P 43/00 (2006.01); C07D 213/72 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01)
CPC (source: EP)
A61P 25/00 (2017.12); A61P 25/06 (2017.12); A61P 25/08 (2017.12); A61P 25/18 (2017.12); A61P 25/20 (2017.12); A61P 25/22 (2017.12); A61P 25/24 (2017.12); A61P 25/28 (2017.12); A61P 25/30 (2017.12); A61P 27/02 (2017.12); A61P 43/00 (2017.12); C07D 401/12 (2013.01); C07D 401/14 (2013.01)
Citation (search report)
See references of WO 9852943A1
Designated contracting state (EPC)
BE CH DE ES FR GB IT LI NL
DOCDB simple family (publication)
WO 9852943 A1 19981126; CA 2290475 A1 19981126; EP 0984956 A1 20000315; GB 9710523 D0 19970716; JP 2001526674 A 20011218
DOCDB simple family (application)
EP 9802992 W 19980513; CA 2290475 A 19980513; EP 98925626 A 19980513; GB 9710523 A 19970523; JP 54996098 A 19980513